MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis

Pharmacogenomics. 2016 Jun;17(9):1005-17. doi: 10.2217/pgs-2016-0004. Epub 2016 Jun 8.

Abstract

Background: MTHFR gene polymorphisms has been shown to be associated with methotrexate (MTX) toxicity in adult hematological malignancies; however, the results remain inconclusive.

Materials & methods: To examine the role of common MTHFR variants in MTX toxicity prediction, we performed a meta-analysis via identifying relevant studies for quantitative data pooling.

Results: Our results showed a significant association between MTHFR C677T polymorphism and increased risk of MTX-induced all-grade (grade 1-4) and severe (grade 3-4) hepatic and gastrointestinal toxicities in Caucasian independent of MTX dosage. MTHFR 677T allele increased risk of severe mucositis and all-grade hematological toxicity. MTHFR A1298C polymorphism was not significantly associated with hepatic and hematological toxicity, whereas perhaps having a protective effect on mucositis and gastrointestinal toxicity.

Conclusion: MTHFR C677T polymorphism may be a good predictor for MTX toxicity in adult hematological malignancies.

Keywords: MTHFR; adult; hematological malignancy; polymorphism; toxicity.

Publication types

  • Meta-Analysis

MeSH terms

  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Hematologic Neoplasms / complications*
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / genetics
  • Humans
  • Methotrexate / adverse effects*
  • Methotrexate / therapeutic use*
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Polymorphism, Genetic / genetics

Substances

  • Antimetabolites, Antineoplastic
  • MTHFR protein, human
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Methotrexate